Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $39.80.
TVRD has been the topic of a number of research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. Finally, HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price target on the stock.
Check Out Our Latest Stock Analysis on TVRD
Tvardi Therapeutics Stock Performance
Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last issued its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Research analysts anticipate that Tvardi Therapeutics will post -2.39 EPS for the current year.
Institutional Trading of Tvardi Therapeutics
A number of institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC purchased a new position in Tvardi Therapeutics in the second quarter valued at about $2,617,000. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at about $39,000. New York State Common Retirement Fund bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $92,000. Marshall Wace LLP bought a new stake in shares of Tvardi Therapeutics in the 2nd quarter valued at approximately $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the second quarter worth approximately $43,000. Institutional investors and hedge funds own 44.66% of the company’s stock.
About Tvardi Therapeutics
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Featured Articles
- Five stocks we like better than Tvardi Therapeutics
- These Stocks Could Win as Wall Street Looks Beyond AI Software
- D.R. Horton Is Defying the Housing Gloom
- Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire
- Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
